CJC-1295 vs Sermorelin
Two GHRH-analog research peptides that differ mainly in duration of action.
CJC-1295 and Sermorelin are both GHRH analogs studied in growth-hormone research. The key difference researchers weigh is duration — CJC-1295, especially with DAC, is longer-acting.
Side-by-side
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Peptide class | GHRH analog | GHRH analog (1-29) |
| Duration note | Longer-acting; DAC version extends half-life | Short-acting in research models |
| Studied mechanism | GHRH-receptor GH release | GHRH-receptor GH release |
| Common research context | Sustained GH-signaling models | GH-axis and aging models |
| Often studied together | Compared to study duration effects | Compared to study duration effects |
Which does the research favor?
Same receptor pathway, different kinetics — CJC-1295 for sustained-signaling research, Sermorelin for shorter-pulse models.
Explore both compounds
Each ships with its Certificate of Analysis. Compare, then choose the compound that fits your research question.
For research use only. These products are intended solely for in-vitro laboratory research and are not for human or veterinary use. Nothing here is medical advice or a therapeutic claim.